[en] BACKGROUND: R126638 is a novel triazole exhibiting potent in vitro and in vivo antifungal activity against fungal pathogens including dermatophytes and yeasts. OBJECTIVE: To determine the antifungal activity in time in the stratum corneum of healthy volunteers after oral intake of R126638 at a daily dose of 100 or 200 mg for 1 week. METHOD: Sixteen male volunteers were randomly allocated to oral treatment with either 100 or 200 mg of R126638 once daily for 1 week. Five cyanoacrylate skin surface strippings (CSSS) were obtained from the forearm of each subject before drug intake at day 1. CSSS were also collected during treatment at day 2 (24 h after the first drug intake, before the second drug intake), at day 4 (before the fourth drug intake) and at day 7 (10 h after the last drug intake). The post-treatment lingering effect was assessed at day 10 (3 days after treatment) and at day 14 (7 days after treatment). The corneofungimetry bioassay was performed on these CSSS to assess the antifungal profile of R126638. Cells of different fungal species (Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Candida albicans and Malassezia globosa) were deposited and cultured for 10 days on CSSS in a sterile and controlled environment. The extent of fungal growth on the stratum corneum was determined using computerized image analysis. RESULTS: R126638 clearly reduced the growth of all tested fungal species. The onset of effects of R126638 was evidenced at day 4 when it reached statistical significance for 3 of 5 species. At day 7, significance was reached for 4 of 5 species. During the posttreatment period, R126638 remained effective for 4 of 5 species at day 10, and this activity persisted until day 14 for 2 of 5 species. CONCLUSION: A broad spectrum antifungal activity was rapidly expressed in the stratum corneum after oral intake of R126638. The drug likely reached the upper layers of the stratum corneum by diffusion and persisted in this location for at least 7 days after treatment.
Disciplines :
Dermatology
Author, co-author :
Pierard, Claudine ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Ausma, Jannie; Barrier Therapeutics (Geel)
Wouters, Luc; Barrier Therapeutics (Geel)
Vroome, Valérie; Barrier Therapeutics (Geel)
Vandeplassche, Lieve; Barrier Therapeutics (Geel)
Borgers, Marcel
Cauwenbergh, Geert
Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Language :
English
Title :
Activity of the triazole antifungal r126638 as assessed by corneofungimetry.
Odds F, Van Gerven F, Woestenborghs F, Meerpoel L, Heeres J, Vanden Bossche A, Borgers M: Activity in vitro and in vivo of a novel azole antifungal agent: R126638. Antimicrob Agents Chemother 2004;48:388-391.
Vanden Bossche H, Ausma J, Bohets H, Vermuyten K, Willemsens G, Marichal P, Meerpoel L, Odds F, Borgers M: The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp. and Microsporum canis. Antimicrob Agents Chemother 2004;48:3272-3278.
Rurangirwa A, Piérard-Franchimont C, Piérard GE: Culture of fungi on cyanoacrylate skin surface strippings: a quantitative bioassay for evaluating antifungal drugs. Clin Exp Dermatol 1989;59:425-428.
Arrese JE, De Doncker P, Odds F, Piérard GE: Reduction in the growth of non-dermatophyte molds by itraconazole: evaluation by the corneofungimetry bioassay. Mycoses 1998;41:461-465.
Knight AG: Culture of dermatophytes upon stratum corneum. J Invest Dermatol 1973;59:427-432.
Faergemann J, Aly R, Maibach HI: Growth and filament production of Pityrosporum orbiculare and P. ovale on human stratum corneum in vitro. Acta Derm Venereol 1983;63:388-392.
Faergemann J: A new model for growth and filament production of Pityrosporum ovale (orbiculare) on human stratum corneum in vitro. J Invest Dermatol 1989;92:117-119.
Aljabre SHM, Richardson MD, Scott EM, Shakland GS: Germination of Trichophyton mentagrophytes on human stratum corneum in vitro. J Med Vet Mycol 1992;30:145-152.
Piérard GE, Rurangirwa A, Piérard-Franchimont C: Bioavailability of fluconazole and ketoconazole in human stratum corneum and oral mucosa. Clin Exp Dermatol 1991;16:167-171.
Piérard GE, Arrese JE, De Doncker P: Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 1995;32:429-435.
Arrese JE, Fogouang L, Piérard-Franchimont C, Piérard GE: Euclidean and fractal computer-assisted corneofungimetry. A comparison of 2% ketoconazole and 1% terbinafine topical formulations. Dermatology 2002;204:222-227.
Piérard GE, Arrese JE, Piérard-Franchimont C: Itraconazole corneofungimetry bioassay on Malassezia species. Mycoses 2004;47:418-421.
Piérard-Franchimont C, Vroome V, Cauwenbergh G, Piérard GE: Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences. Skin Pharmacol Physiol 2005;18:98-102.
Gallo RL, Murakami M, Ohtake T, Zaiou M: Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 2002;110:823-831.
Janeway CA, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
Zasloff M: Antimicrobial peptides of multicellular organisms. Nature 2002;415:389-395.
Dorschner RA, Lopez-Garcia B, Massie J, Kim C, Gallo RL: Innate immune defense of the nail unit by antimicrobial peptides. J Am Acad Dermatol 2004;50:343-348.
Roeder A, Kirschning CJ, Rupee RA, Schaller M, Weindl G, Korting HC: Toll-like receptors as key mediators in innate antifungal immunity. Med Mycol 2004;42:485-498.
Naka W, Hanyaku H, Tajima S, Harada T, Nishikawa T: Application of neutral red staining for evaluation of the viability of dermatophytes and Candida in human skin scales. J Med Vet Mycol 1994;32:31-35.
SAS Procedures Guide, version 8, Cary, SAS Institute Inc., 1999.
Osborne CS, Leitner I, Favre B, Ryder NS: Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol 2004;42:159-163.
Arrese JE, Piérard GE: Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology 2003;207:255-260.
Ausma J, Bruynseels J, Snoeck E, Blockhuys S, van Rossem K, Borgers M: Placebo-controlled randomized double-blind multiple dose dose-rising trial in healthy volunteers to assess tolerability, safety and pharmacokinetics of the novel antifungal R126638. J Eur Acad Dermatol Venereol 2004;18(suppl 2):392.
Piérard-Franchimont C, Piérard GE, Arrese JE, De Doncker P: Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology 2001;202:171-176.
Faergemann J, Bergbrant IM, Dohse M, Scott A, Westgate G: Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001;144:549-556.
Faergemann J: Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol 2000;1:75-80.
Piérard GE, Piérard-Franchimont C, Van Cutsem J, Rurangirwa A, Hoppenbrouwers ML, Schrooten P: Ketoconazole 2% emulsion in the treatment of seborrheic dermatitis. Int J Dermatol 1991;30:806-809.
Piérard GE: Seborrheic dermatitis today, gone tomorrow? The link between the bioscene and treatment. Dermatology 2003;206:233-240.
Meerpoel L, Backx L, Van der Veken L, Heeres J, Corens D, De Groot A, Odds F, Van Gerven F, Woestenborghs F, Van Breda A, Oris M, Van Dorsselaer P, Willemsens G, Vermuyten K, Marichal P, Vanden Bossche H, Ausma J, Borgers M: Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. J Med Chem 2005;48:2184-2193.
